Major trial launched to explore GLP-1 benefit in dementia
A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
Newsletters and Deep Dive digital magazine
A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.
The desire for patients to be active partners in research challenges how organisations approach patient engagement.
A strong end-of-life care system does not wait until the final days to step in.
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
Editor's Picks
Newsletters and Deep Dive
digital magazine